Radium 223 for bone metastases in advanced prostate cancer

from The JNCI Podcast · host Oxford University Press

Dr. Chris Parker, lead investigator of the international ALSYMPCA trial of radium 223 (Alpharadin) for bone metastases in advanced prostate cancer, discusses the trial and future of this therapy following his lecture at the recent ECCO-ESMO Cancer Congress in Stockholm.

Episode metadata supplied by the publisher feed · Published Oct 12, 2011

Embed this episode

Attribution link and audio player

NOW PLAYING

Radium 223 for bone metastases in advanced prostate cancer

0:00 6:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The JNCI Podcast?

This episode is 6 minutes long.

When was this The JNCI Podcast episode published?

This episode was published on October 12, 2011.

Can I download this The JNCI Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!